#153600

KPC Cell Line (mixed genetic background)

Please Enter Your Email ID
Email ID

Cat. #153600

KPC Cell Line (mixed genetic background)

Cat. #: 153600

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Availability: 3-5 days

Organism: Mouse

Disease: Cancer

Model: Transgenic

£800.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Jennifer Morton

Institute: Cancer Research UK, Glasgow Beatson Institute

Tool Details
Target Details
Applications
Handling
Related Tools
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: KPC Cell Line (mixed genetic background)
  • Alternate name: PDAC cell line
  • Cancer: Pancreatic cancer
  • Cancers detailed: Pancreatic cancer ; Pancreatic ductal adenocarcinoma
  • Research fields: Cancer;Drug development
  • Tool sub type: Continuous
  • Organism: Mouse
  • Disease: Cancer
  • Model: Transgenic
  • Conditional: No
  • Description: This KPC cell line represents a useful model of pancreatic ductal adenocarcinoma. This cell line was established from a popular KPC mouse model (Hingorani et al. 2005). It has a mixed genetic background.

    Details on source mouse model
    The KPC mice from which the KPC cell is derived, are an establish clinically relevant model of PDA, that develop many of the key features of observed in human PDA such as pancreatic intraepithelial neoplasia. The KPC mouse contains a conditional point mutation in the transformation related protein 53 gene (TP53R172H), and a point mutation in the KRAS gene (KRASG12D) both of which generate non-functional proteins. A lox-stop-lox termination sequence is encoded upstream of both mutated genes to prevent expression in the absence of Cre recombinase. PDX1 (pancreatic and duodenal homeobox 1) is a transcription factor necessary for pancreatic development. The PDX1 promoter enables expression of Cre recombinase in acini, islet and duct cells of the pancreas. Cre-mediated recombination excises the two lox-stop-lox termination sequences and enables expression of both oncogenes: KRASG12D and TP53R172H in pancreatic tissue. Tissues not expressing Cre recombinase remain functionally heterozygous of the KRAS and TRP53 loci.

    KPC cell line
    The KPC cell line was derived from a KPC model that has a mixed genetic background. This cell line retains the mutations seen in the parental KPC murine model. This KPC model can be used for PDA modelling, biomarkers investigation, genetics, and metastasis studies as well as drug discovery and development.
  • Biosafety level: 1
  • Additional notes: These cells are from mice with a mixed genetic background

Target Details

  • Target: TP53, KRAS

Applications

  • Application notes: These cells are from mice with a mixed genetic background

Handling

  • Format: Frozen
  • Growth medium: DMEM +10% FCS, 1% L-Glut and 1% Pen/strep. Revival might be slow.
  • Temperature: 38 ° C
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice
  • Storage conditions: Liquid Nitrogen
  • Mycoplasma free: Yes

Related Tools

  • Related tools: KPC Cell Line (C57/BL6 genetic background)

References

  • Li et al. 2014. Gastroenterology. 146(5):1386-96.e1-17. PMID: 24462734.
  • Hingorani et al. 2005. Cancer Cell. 7(5):469-83. PMID: 15894267.